Brendan Eckelman
Founder at INHIBRX, INC.
Net worth: 80 M $ as of 2024-04-29
Brendan Eckelman active positions
| Companies | Position | Start | End |
|---|---|---|---|
| INHIBRX, INC. | Founder | 2010-03-31 | - |
| Chief Tech/Sci/R&D Officer | - | - | |
| Director/Board Member | 2018-03-31 | 2021-10-26 |
Career history of Brendan Eckelman
Former positions of Brendan Eckelman
| Companies | Position | Start | End |
|---|---|---|---|
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - | - |
Inhibrx LP
 Inhibrx LP BiotechnologyHealth Technology Inhibrx LP developed therapeutic antibodies and pharmaceuticals. Its programs focused on oncology, inflammatory and metabolic diseases and these programs are based on an implementation of multiple antibody and biologic development strategies for therapeutic lead generation, selection, functional enhancement, and optimization. The firm's platforms enabled fit-for-function biotherapeutics that interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. The company was founded by Quinn Deveraux, Brendan Eckelman, and Mark Paul Lappe in 2010 and was headquartered in La Jolla, CA. | Chief Operating Officer | 2009-12-31 | - |
| Founder | 2009-12-31 | - |
Training of Brendan Eckelman
| UC San Diego School of Medicine | Doctorate Degree |
| University of California San Diego | Graduate Degree |
Statistics
International
| United States | 6 |
Operational
| Founder | 2 |
| Chief Operating Officer | 1 |
| Corporate Officer/Principal | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| INHIBRX, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Inhibrx LP
Inhibrx LP BiotechnologyHealth Technology Inhibrx LP developed therapeutic antibodies and pharmaceuticals. Its programs focused on oncology, inflammatory and metabolic diseases and these programs are based on an implementation of multiple antibody and biologic development strategies for therapeutic lead generation, selection, functional enhancement, and optimization. The firm's platforms enabled fit-for-function biotherapeutics that interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. The company was founded by Quinn Deveraux, Brendan Eckelman, and Mark Paul Lappe in 2010 and was headquartered in La Jolla, CA. | Health Technology |
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Commercial Services |
- Stock Market
- Insiders
- Brendan Eckelman
- Experience
